Dupixent Europäische Union - Deutsch - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - mittel gegen dermatitis, ausgenommen corticosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Valproat Chrono Winthrop 300 mg Retardtabletten Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

valproat chrono winthrop 300 mg retardtabletten

sanofi-aventis deutschland gmbh - natriumvalproat, valproinsäure - retardtablette - natriumvalproat 199.8mg; valproinsäure 87.mg

Valproat Chrono Winthrop 500 mg Retardtabletten Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

valproat chrono winthrop 500 mg retardtabletten

sanofi-aventis deutschland gmbh - natriumvalproat, valproinsäure - retardtablette - natriumvalproat 333.mg; valproinsäure 145.mg

Sarclisa Europäische Union - Deutsch - EMA (European Medicines Agency)

sarclisa

sanofi winthrop industrie - isatuximab - multiples myelom - antineoplastische mittel - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Truvelog Mix 30 Europäische Union - Deutsch - EMA (European Medicines Agency)

truvelog mix 30

sanofi winthrop industrie - insulin aspart - diabetes mellitus - drogen bei diabetes verwendet - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

Ultracain D-S forte Sanofi-Aventis 1:100.000 1,7 ml Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ultracain d-s forte sanofi-aventis 1:100.000 1,7 ml

sanofi-aventis deutschland gmbh (8030868) - articainhydrochlorid; epinephrinhydrochlorid - injektionslösung - teil 1 - injektionslösung; articainhydrochlorid (10986) 40 milligramm; epinephrinhydrochlorid (00719) 0,012 milligramm

Ultracain D-S Sanofi-Aventis 1:200.000 1,7 ml Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ultracain d-s sanofi-aventis 1:200.000 1,7 ml

sanofi-aventis deutschland gmbh (8030868) - articainhydrochlorid; epinephrinhydrochlorid - injektionslösung - teil 1 - injektionslösung; articainhydrochlorid (10986) 40 milligramm; epinephrinhydrochlorid (00719) 0,006 milligramm

Buprenorphin Sanofi 8 mg Sublingualtabletten Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

buprenorphin sanofi 8 mg sublingualtabletten

sanofi-aventis deutschland gmbh (8030868) - buprenorphinhydrochlorid - sublingualtablette - teil 1 - sublingualtablette; buprenorphinhydrochlorid (20181) 8,64 milligramm

Buprenorphin Sanofi 2 mg Sublingualtabletten Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

buprenorphin sanofi 2 mg sublingualtabletten

sanofi-aventis deutschland gmbh (8030868) - buprenorphinhydrochlorid - sublingualtablette - teil 1 - sublingualtablette; buprenorphinhydrochlorid (20181) 2,16 milligramm

Tranxilium 50 Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

tranxilium 50

sanofi-aventis deutschland gmbh (8030868) - dikaliumclorazepat - filmtablette - teil 1 - filmtablette; dikaliumclorazepat (04729) 50 milligramm